Pacira BioSciences (PCRX) FY2015 results: revenue $249 million, up 26.0% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $249 million for fiscal 2015, the year ended 31 December 2015, up 26.0% on the year before. Net income was $2 million, and diluted earnings per share $0.04. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2016.
Revenue
$249 million
+26.0% on the year
FY2009FY2015
Operating margin
3.8%
-2.6% a year earlier
FY2009FY2015
Net income
$2 million
FY2009FY2015
Diluted EPS
$0.04
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
249
198
85.6
+26.0%
Cost of revenue
71.8
77.4
54.8
-7.2%
Gross profit
177
120
30.8
+47.4%
Gross margin
71.1%
60.8%
36.0%
Research and development
28.7
18.7
21.6
+53.0%
Selling, general and administrative
139
107
62.5
+30.4%
Operating income
9.5
-5.2
-53.3
Operating margin
3.8%
-2.6%
-62.3%
Interest expense
7.7
8.3
7.3
-6.7%
Pre-tax income
2.1
-13.5
-64.4
Income tax
0.3
0.2
-0.4
+52.6%
Effective tax rate
12.5%
n/a
n/a
Net income
1.9
-13.7
-63.9
Net margin
0.7%
-6.9%
-74.7%
Diluted EPS
$0.04
-$0.39
-$1.93
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
28.0
n/a
-43.8
Capital expenditure
40.3
23.0
12.2
+75.3%
Free cash flow
-12.3
n/a
-56.0
Free cash flow margin
-4.9%
n/a
-65.5%
Depreciation and amortisation
11.5
10.0
5.7
+14.3%
Share-based compensation
33.4
24.8
11.5
+34.4%
Diluted shares, weighted
41m
35m
33m
+17.0%
Shares outstanding at period end
37m
36m
34m
+1.9%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
218
171
41.2
+27.6%
Debt
104
103
99.0
+0.9%
Other liabilities
65.3
51.8
29.6
+26.0%
Total liabilities and equity
388
326
170
+18.9%
Fixed assets
90.3
60.6
48.2
+49.0%
Goodwill
30.9
23.8
10.3
+30.0%
Intangible assets
0.1
0.4
1.2
-79.9%
Investments
115
144
59.6
-19.6%
Cash and equivalents
57.0
37.5
12.5
+51.9%
Receivables
25.9
22.4
14.6
+15.6%
Inventory
61.6
29.3
15.6
+110.7%
Other assets
6.5
8.6
7.9
-23.8%
Total assets
388
326
170
+18.9%
10-K for the year ended 31 December 2015, filed 25 February 2016: the filing.